Ex-Trump official-ran Altesa secures $75m in Series B funding round
Altesa BioSciences has closed an oversubscribed $75m Series B funding round to advance the clinical development of its antiviral, vapendavir.…
20 Feb 2026
WHO wants improved universal vaccines to win global influenza battle
The World Health Organization (WHO) has outlined the benefits that improved influenza vaccines could offer, as the agency seeks to overcome a more hesitant vaccine development sector in the US.…
20 Feb 2026
Boehringer Ingelheim and NIPER sign MoU on pharmaceutical research
Boehringer Ingelheim India has signed a memorandum of understanding (MoU) to enhance pharmaceutical education and research collaboration. The MoU with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli,…
20 Feb 2026
Syngene and VivaMed collaborate on therapeutic programmes
Syngene International has entered a strategic collaboration with VivaMed BioPharma to advance AI-derived repurposed therapeutic programmes. This partnership aims to broaden VivaMed’s validation infrastructure for AI-driven drug repurposing partnership programmes…
19 Feb 2026
Valneva’s Lyme disease vaccine offers beacon of hope amid 2025 sales dip
Valneva reported a drop in product sales in 2025 amid market restrictions for chikungunya vaccine Ixchiq, with the travel vaccine specialist betting on upcoming readouts to turn the business’ growth…
19 Feb 2026
J&J to build $1bn US CGT manufacturing site in Pennsylvania
Johnson & Johnson (J&J) has chosen Pennsylvania as home to its new $1bn cell therapy manufacturing facility, as the Trump administration looks to onshore drug production to the US amid…
19 Feb 2026
Novartis enters licensing agreement with UNP for peptide therapeutics
Novartis has signed a research partnership and licensing agreement with Unnatural Products (UNP) valued at up to $1.7bn to develop macrocyclic peptide therapeutics targeting cardiovascular diseases. The partnership combines UNP’s…